MAPK1 and non-small cell lung carcinoma: In addition, clinical studies of oral ONC201 are underway in patients with relapsed non-hodgkin’s lymphoma, adult recurrent glioblastoma, and relapsed acute leukemia, etc. Even though our data reveal the importance of the ERK signaling in gefitinib-resistant NSCLC cells, there are still many unanswered questions left: how the ERK signaling is enhanced during the gefitinib resistance, and how it promotes autophagy.